BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Updated Information Regarding SRM Entertainment Spin-Off, Closes on Safety Shot Acquisition

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has released the updated payment date for the distribution of shares of common stock, par value $0.0001 per share, of SRM Entertainment Inc. SRM Entertainment is currently a majority-owned subsidiary of Jupiter Wellness. According to the announcement, the date to effect the spin-off of the SRM business is planned for Aug. 14, 2023; the payment date remains subject to SRM’s Registration Statement on Form S-1 being declared effective by the U.S. Securities and Exchange Commission. “In the event that such registration statement is not declared effective or the SRM common stock is not approved for listing, the distribution will not be paid on such date and the spin-off transaction will not occur,” the company stated in the press release. “The company anticipates that the SRM common stock will begin trading on the NASDAQ Capital Market on Aug. 15, 2023.”

In addition, Jupiter Wellness closed the acquisition of all operating assets — including the formula, patent, know-how, clinical data and inventory of the world’s first rapid blood alcohol detox drink — of GBB Drink Lab Inc. Dubbed Safety Shot, the detoxification product was created by a doctor, is patented and has been validated by initial research to lower blood alcohol content by up to 50% in only 30 minutes. According to the announcement, Safety Shot targets the alcohol hangover remedy market, which is projected at $1.56 billion. The company also noted that several members of GBB Drink Lab’s executive team, as well as board members and advisors, have joined Jupiter Wellness. The company anticipates that a significant amount of its revenues will be driven by the Safety Shot business unit moving forward; consequently, the company plans to change its name to Safety Shot. “We couldn’t be more excited about closing this acquisition as our company is now positioned to launch a first-of-its kind wellness product that we believe will huge implications and benefits on wellness and safety around alcohol consumption,” said Jupiter Wellness CEO Brian John in the press release. “With key members of the Safety Shot team now on our team, a successful launch of this critical product is well underway. While we continue to execute on our portfolio of other health and wellness products, Safety Shot is the company’s primary focus going forward. We see this is a tremendous win for Jupiter shareholders.”

To view the full press releases, visit https://ibn.fm/hXVYd and https://ibn.fm/6wYy9

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, psoriasis and vitiligo. Revenue is generated through the sales of OTC and consumer products as well as licensing royalties. For additional information about this company, visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Preps ONC010 for Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations…

8 hours ago

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

13 hours ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the…

1 day ago

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Adds California Hub to Growing Pharmacy Network

Earth Science Tech (OTC: ETST) recently continued its expansion in the healthcare, pharmacy and telemedicine…

1 day ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725…

2 days ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing…

7 days ago